YONSA

This brand name is authorized in New Zealand, United States

Active ingredients

The drug YONSA contains one active pharmaceutical ingredient (API):

1 Abiraterone UNII EM5OCB9YJ6 - ABIRATERONE ACETATE

Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals. Read about Abiraterone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
YONSA Tablet		MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02BX03	Abiraterone	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 20961
Country: US	FDA, National Drug Code	Identifier(s): 47335-401